

Matteo Bassetti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2464371/matteo-bassetti-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

367
papers

14,026
citations

59
h-index

105
g-index

421
ext. papers

19,018
ext. citations

7.2
avg, IF

6.9
L-index

#	Paper	IF	Citations
367	New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022 ,	3.9	2
366	Re: Rime to blood culture positivity in Staphylococcus aureus bacteraemia to determine risk of infective endocarditisRby Kahn et al.. <i>Clinical Microbiology and Infection</i> , 2022 ,	9.5	
365	Surgical Site Infection after Cardiac Surgery in the COVID-19 Era: A Case Report.. <i>Infectious Disease Reports</i> , 2022 , 14, 101-105	0.6	
364	Efficacy and Safety of Carbapenems vs New Antibiotics for Treatment of Adult Patients With Complicated Urinary Tract Infections: A Systematic Review and Meta-analysis.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofaa480	1	0
363	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study.. <i>Infectious Diseases and Therapy</i> , 2022 , 11, 827-840	6.2	0
362	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing : a multicentre study.. <i>JAC-Antimicrobial Resistance</i> , 2022 , 4, dlac022	2.9	3
361	Understanding the pathophysiology of typical acute respiratory distress syndrome and severe COVID-19.. <i>Expert Review of Respiratory Medicine</i> , 2022 , 1-10	3.8	0
360	Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study.. <i>Journal of Clinical Microbiology</i> , 2022 , e0229821	9.7	2
359	Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.. <i>Cell Reports Medicine</i> , 2022 , 3, 100560	18	3
358	Antibiotic treatment of acute bacterial skin and skin structure infections.. <i>Current Opinion in Infectious Diseases</i> , 2022 , 35, 120-127	5.4	0
357	Early versus late intubation in COVID-19 patients failing helmet CPAP: a quantitative computed tomography study.. <i>Respiratory Physiology and Neurobiology</i> , 2022 , 103889	2.8	1
356	Candida auris Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk Factors.. <i>Infectious Diseases and Therapy</i> , 2022 , 1	6.2	8
355	Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by : A Comprehensive Review of the Evidence.. <i>Infection and Drug Resistance</i> , 2022 , 15, 2137-2157	4.2	1
354	Improving management and antimicrobial stewardship for bacterial and fungal infections in hospitalized patients with COVID-19.. <i>Therapeutic Advances in Infectious Disease</i> , 2022 , 9, 20499361221095732	2.8	0
353	A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2021 , 11, 635	6.2	1
352	All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.. <i>Expert Review of Anti-Infective Therapy</i> , 2021 ,	5.5	2
351	European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine).. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	27

350	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. <i>Lancet Infectious Diseases, The</i> , 2021 ,	25.5	0
349	Enterococcal bloodstream infections in critically ill patients with COVID-19: a case series. <i>Annals of Medicine</i> , 2021 , 53, 1779-1786	1.5	4
348	Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections. <i>Expert Opinion on Drug Safety</i> , 2021 , 1-12	4.1	0
347	Timing of antibiotic therapy in the ICU. <i>Critical Care</i> , 2021 , 25, 360	10.8	5
346	A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: A SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement. <i>Respiratory Medicine</i> , 2021 , 190, 106674	4.6	1
345	Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. <i>Current Opinion in Infectious Diseases</i> , 2021 , 34, 109-117	5.4	2
344	The Importance of Quantitative Results of a Lateral Flow Aspergillus Assay: The Significant Impact on Specificity. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1783-e1784	11.6	1
343	Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3647-e3655	11.6	22
342	Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Infections. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
341	Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. <i>Critical Care</i> , 2021 , 25, 111	10.8	20
340	EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. <i>Clinical Infectious Diseases</i> , 2021 , 72, S121-S127	11.6	21
339	The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 1125-1134	5.5	3
338	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab217	1	16
337	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. <i>PLoS Pathogens</i> , 2021 , 17, e1009448	7.6	18
336	Antiviral treatment selection for SARS-CoV-2 pneumonia. <i>Expert Review of Respiratory Medicine</i> , 2021 , 15, 985-992	3.8	1
335	A Wide Database for Future Studies Aimed at Improving Early Recognition of Candidemia. <i>Studies in Health Technology and Informatics</i> , 2021 , 281, 1081-1082	0.5	
334	Characterization of T lymphocytes in severe COVID-19 patients. <i>Journal of Medical Virology</i> , 2021 , 93, 5608-5613	19.7	10
333	An Experimental Pre-Post Study on the Efficacy of Respiratory Physiotherapy in Severe Critically Ill COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2

332	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021 , 47, 819-834	14.5	30
331	Lung distribution of gas and blood volume in critically ill COVID-19 patients: a quantitative dual-energy computed tomography study. <i>Critical Care</i> , 2021 , 25, 214	10.8	18
330	Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. <i>Journal of Global Antimicrobial Resistance</i> , 2021 , 25, 268-281	3.4	17
329	Use of Ceftriaxone in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study. <i>Antibiotics</i> , 2021 , 10,	4.9	1
328	Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. <i>Journal of Global Antimicrobial Resistance</i> , 2021 , 25, 346-350	3.4	1
327	Early Effects of Passive Leg-Raising Test, Fluid Challenge, and Norepinephrine on Cerebral Autoregulation and Oxygenation in COVID-19 Critically Ill Patients. <i>Frontiers in Neurology</i> , 2021 , 12, 674465	4.1	6
326	Early infections after successful transcatheter aortic valve replacement are associated with increased short- and long-term mortality: A single-center study. <i>International Journal of Cardiology</i> , 2021 , 332, 48-53	3.2	
325	The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome. <i>Frontiers in Medicine</i> , 2021 , 8, 671714	4.9	7
324	Placing in-vitro heteroresistance in the context of clinical results. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 908-909	25.5	1
323	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2021 , 10, 1837-1885	6.2	10
322	Systemic fibrinolysis for acute pulmonary embolism complicating acute respiratory distress syndrome in severe COVID-19: a case series. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 78-80	6.4	6
321	Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. <i>Journal of Nephrology</i> , 2021 , 34, 173-183	4.8	26
320	Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant <i>Acinetobacter baumannii</i> : A Prospective, Observational Study. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 187-200	6.2	18
319	Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s?. <i>Intensive Care Medicine</i> , 2021 , 47, 104-106	14.5	11
318	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 226-240	25.5	147
317	Will vaccine hesitancy compromise our efforts to face the next SARS-CoV-2 epidemic wave?. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 1664-1665	4.4	1
316	Response. <i>Chest</i> , 2021 , 159, 1677-1678	5.3	
315	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e149-e162	25.5	242

314	Therapeutic options for difficult-to-treat A infections: a 2020 perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 167-177	4	11
313	Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications. <i>Current Opinion in Infectious Diseases</i> , 2021 , 34, 96-108	5.4	5
312	Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 387-398	6.3	9
311	Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1664-1676	11.6	32
310	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	28
309	Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia. <i>Critical Care</i> , 2021 , 25, 81	10.8	31
308	The Impact of Carbapenem Resistance on Mortality in Patients With Klebsiella Pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 541-558	6.2	4
307	Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 983-991	5.5	3
306	Early Detection of Sepsis With Machine Learning Techniques: A Brief Clinical Perspective. <i>Frontiers in Medicine</i> , 2021 , 8, 617486	4.9	10
305	Single Strain High-Depth NGS Reveals High rDNA (ITS-LSU) Variability in the Four Prevalent Pathogenic Species of the Genus. <i>Microorganisms</i> , 2021 , 9,	4.9	3
304	Efficacy and safety of eravacycline: A meta-analysis. <i>Journal of Global Antimicrobial Resistance</i> , 2021 , 24, 424-428	3.4	5
303	New antibiotics for the treatment of nonfermenting Gram-negative bacteria. <i>Current Opinion in Infectious Diseases</i> , 2021 , 34, 701-709	5.4	0
302	Recent advances and future perspectives in the pharmacological treatment of infections. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 1205-1220	3.8	3
301	Diagnosis and treatment of COVID-19 associated pulmonary aspergillosis in critically ill patients: results from a European confederation of medical mycology registry. <i>Intensive Care Medicine</i> , 2021 , 47, 1158-1160	14.5	17
300	Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care. <i>European Journal of Internal Medicine</i> , 2021 , 94, 39-44	3.9	2
299	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases</i> , 2021 , 21, 211-227	25.5	40
298	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	31
297	Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions. <i>Archives of Medical Research</i> , 2021 , 52, 817-827	6.6	3

296	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , 2021 , 27, 1752-1760 ^{50.5}	93
295	Role of new antibiotics in extended-spectrum β -lactamase-, AmpC- infections. <i>Current Opinion in Infectious Diseases</i> , 2021 , 34, 748-755	5.4 4
294	Complicated carbapenem-resistant infections: a treatment pathway analysis in Italian sites.. <i>Infezioni in Medicina</i> , 2021 , 29, 434-449	3.6 1
293	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology, The</i> , 2021 , 3, e690-e697	14.2 38
292	Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 88, 132-137	3.1 4
291	Personal protective equipment use by healthcare workers in intensive care unit during the early phase of COVID-19 pandemic in Italy: a secondary analysis of the PPE-SAFE survey. <i>Therapeutic Advances in Infectious Disease</i> , 2021 , 8, 2049936121998562	2.8 10
290	Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, iv23-iv37	5.1 3
289	Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia.. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 1-8	5.5 1
288	Current pharmacotherapy for methicillin-resistant (MRSA) pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-14	4 1
287	The Use of Different Components of Brain Oxygenation for the Assessment of Cerebral Haemodynamics: A Prospective Observational Study on COVID-19 Patients.. <i>Frontiers in Neurology</i> , 2021 , 12, 735469	4.1 0
286	Clinical Features and Mortality of Nosocomial Candidemia in Very Old Patients: A Multicentre Italian Study. <i>Gerontology</i> , 2020 , 66, 532-541	5.5 3
285	Saprochaete capitata aortitis in an immunocompetent patient after myocardial revascularization. <i>Cardiovascular Pathology</i> , 2020 , 48, 107223	3.8 1
284	How to manage KPC infections. <i>Therapeutic Advances in Infectious Disease</i> , 2020 , 7, 2049936120912049	2.8 14
283	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. <i>Intensive Care Medicine</i> , 2020 , 46, 1127-1153	14.5 184
282	High prevalence of olfactory and taste disorder during SARS-CoV-2 infection in outpatients. <i>Journal of Medical Virology</i> , 2020 , 92, 2310-2311	19.7 24
281	Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020 , 279, 103455	2.8 94
280	Diagnosing COVID-19-associated pulmonary aspergillosis. <i>Lancet Microbe, The</i> , 2020 , 1, e53-e55	22.2 115
279	Bloodstream infections in critically ill patients with COVID-19. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13319	4.6 118

278	Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam. <i>Infection and Drug Resistance</i> , 2020 , 13, 1763-1773	4.2	4
277	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020 , 46, 1524-1535	14.5	149
276	Role of Antifungal Therapy in Complicated Intra-abdominal Infections. <i>Current Infectious Disease Reports</i> , 2020 , 22, 1	3.9	1
275	Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey. <i>Journal of Critical Care</i> , 2020 , 59, 70-75	4	110
274	The interplay between acute bacterial skin and skin structure infections and depression: a vicious circle of major clinical importance. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 155-165	5.4	2
273	Therapeutic Potential of the Gut Microbiota in the Management of Sepsis. <i>Critical Care</i> , 2020 , 24, 105	10.8	12
272	Hot topics in diabetic foot infection. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105942	14.3	4
271	Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 110-120	5.4	7
270	Salvage heart transplantation for Mycoplasma hominis prosthetic valve endocarditis: A case report and review of the literature. <i>Transplant Infectious Disease</i> , 2020 , 22, e13249	2.7	2
269	Mould Infections of Traumatic Wounds: A Brief Narrative Review. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 1-15	6.2	15
268	Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child-Pugh B or C Liver Disease: A Case-Control Retrospective Study. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 151-163	6.2	3
267	Bloodstream infections in critically ill patients: an expert statement. <i>Intensive Care Medicine</i> , 2020 , 46, 266-284	14.5	47
266	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant. <i>Antibiotics</i> , 2020 , 9,	4.9	27
265	Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105921	14.3	6
264	Characterisation and risk factor profiling of Pseudomonas aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105900	14.3	5
263	Changes in the relative prevalence of candidaemia due to non-albicans Candida species in adult in-patients: A systematic review, meta-analysis and meta-regression. <i>Mycoses</i> , 2020 , 63, 334-342	5.2	13
262	Machine Learning and Multidrug-Resistant Gram-Negative Bacteria: An Interesting Combination for Current and Future Research. <i>Antibiotics</i> , 2020 , 9,	4.9	4
261	Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy. <i>Clinical Therapeutics</i> , 2020 , 42, 802-817	3.5	2

260	Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant : advances in phase I and II trials. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 495-506	5.9	10
259	Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. <i>Journal of Infectious Diseases</i> , 2020 , 221, 356-366	7	10
258	Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing <i>Klebsiella pneumoniae</i> . <i>Critical Care</i> , 2020 , 24, 29	10.8	46
257	The role of new antimicrobials for Gram-negative infections in daily clinical practice. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 495-500	5.4	7
256	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. <i>Infection and Drug Resistance</i> , 2020 , 13, 4697-4711	4.2	12
255	Overcoming Antibiotic Resistance: New Perspectives. <i>Human Perspectives in Health Sciences and Technology</i> , 2020 , 457-480	0.3	
254	A Systematic Review of the Effect of Delayed Appropriate Antibiotic Treatment on the Outcomes of Patients With Severe Bacterial Infections. <i>Chest</i> , 2020 , 158, 929-938	5.3	19
253	Treatment of extended-spectrum β -lactamases infections: what is the current role of new β -lactams/ β -lactamase inhibitors?. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 474-481	5.4	6
252	Post-operative abdominal infections: epidemiology, operational definitions, and outcomes. <i>Intensive Care Medicine</i> , 2020 , 46, 163-172	14.5	10
251	Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. <i>Journal of Medical Economics</i> , 2020 , 23, 148-155	2.4	
250	Incremental value of FDG-PET/CT to monitor treatment response in infectious spondylodiscitis. <i>Skeletal Radiology</i> , 2020 , 49, 903-912	2.7	7
249	Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 2020 , 71, 1799-1801	11.6	13
248	Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. <i>Lancet Infectious Diseases</i> , 2020 , 20, 330-340	25.5	38
247	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6	607
246	Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	18
245	Conventional amphotericin B must be avoided in <i>Candida</i> infections. <i>Intensive Care Medicine</i> , 2020 , 46, 560-561	14.5	2
244	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). <i>Intensive Care Medicine</i> , 2020 , 46, 245-265	14.5	45
243	Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance. <i>Antibiotics</i> , 2020 , 9,	4.9	17

242	Chest physiotherapy: An important adjuvant in critically ill mechanically ventilated patients with COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020 , 282, 103529	2.8	21
241	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. <i>PLoS ONE</i> , 2020 , 15, e0240550	3.7	1
240	Brain microvascular occlusive disorder in COVID-19: a case report. <i>Neurological Sciences</i> , 2020 , 41, 3401-3404	3.9	10
239	Inhaled Liposomal Antimicrobial Delivery in Lung Infections. <i>Drugs</i> , 2020 , 80, 1309-1318	12.1	30
238	Neurological Complications and Noninvasive Multimodal Neuromonitoring in Critically Ill Mechanically Ventilated COVID-19 Patients. <i>Frontiers in Neurology</i> , 2020 , 11, 602114	4.1	20
237	Treatment of severe infections due to metallo-β-lactamases-producing Gram-negative bacteria. <i>Future Microbiology</i> , 2020 , 1489-1505	2.9	10
236	Induction of ketosis as a potential therapeutic option to limit hyperglycemia and prevent cytokine storm in COVID-19. <i>Nutrition</i> , 2020 , 79-80, 110967	4.8	13
235	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13358	4.6	2
234	Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106104	14.3	6
233	Neurological Manifestations of Severe SARS-CoV-2 Infection: Potential Mechanisms and Implications of Individualized Mechanical Ventilation Settings. <i>Frontiers in Neurology</i> , 2020 , 11, 845	4.1	31
232	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1537-1544	9.5	50
231	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa233	1	2
230	A very rare case of mycobacterium gordonae infection of the breast. <i>Breast Journal</i> , 2020 , 26, 2229-2232	1.2	0
229	Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	45
228	Adequate duration of therapy in severe fungal infections. <i>Current Opinion in Critical Care</i> , 2020 , 26, 466-472	3.7	1
227	Neuroinvasive West Nile Infection with an Unusual Clinical Presentation: A Single-Center Case Series. <i>Tropical Medicine and Infectious Disease</i> , 2020 , 5,	3.5	2
226	Bacterial and fungal superinfections in critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2020 , 46, 2071-2074	14.5	50
225	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <i>PLoS ONE</i> , 2020 , 15, e0237831	3.7	62

224	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. <i>Microorganisms</i> , 2020 , 8,	4.9	3
223	Use of colistin in adult patients: A cross-sectional study. <i>Journal of Global Antimicrobial Resistance</i> , 2020 , 20, 43-49	3.4	16
222	Role of procalcitonin in predicting etiology in bacteremic patients: Report from a large single-center experience. <i>Journal of Infection and Public Health</i> , 2020 , 13, 40-45	7.4	10
221	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa139	1	24
220	Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	3
219	Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts. <i>Critical Care</i> , 2020 , 24, 117	10.8	10
218	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia 2020 , 15, e0237831		
217	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia 2020 , 15, e0237831		
216	Should High-dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 695-702	6.2	7
215	Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3588-3595	5.1	12
214	Enriching the antibiotic armamentarium for acute bacterial skin and skin structure infections. <i>Lancet Infectious Diseases</i> , 2019 , 19, 1037-1039	25.5	1
213	Combating resistance while maintaining innovation: the future of antimicrobial stewardship. <i>Future Microbiology</i> , 2019 , 14, 1331-1341	2.9	9
212	Fungal Endogenous Endophthalmitis Secondary to. <i>Case Reports in Ophthalmology</i> , 2019 , 10, 292-298	0.7	1
211	Ceftobiprole: drug evaluation and place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 689-698	5.5	22
210	Serological and T Cell Responses After Varicella Zoster Virus Vaccination in HIV-Positive Patients Undergoing Renal Dialysis. <i>Viral Immunology</i> , 2019 , 32, 151-157	1.7	2
209	Immunological profiles of HIV-positive recipients of liver transplant. <i>Transplant Immunology</i> , 2019 , 57, 101208	1.7	2
208	The safety of treatment options for acute bacterial skin and skin structure infections. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 635-650	4.1	17
207	Procalcitonin levels in candidemia versus bacteremia: a systematic review. <i>Critical Care</i> , 2019 , 23, 190	10.8	21

206	Bloodstream infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i> : Clinical features, therapy and outcome from a multicenter study. <i>Journal of Infection</i> , 2019 , 79, 130-138	18.9	31
205	Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1711-1718	4	22
204	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. <i>Critical Care</i> , 2019 , 23, 219	10.8	64
203	Treatment of <i>Candida</i> infections with fluconazole in adult liver transplant recipients: Is TDM-guided dosing adaptation helpful?. <i>Transplant Infectious Disease</i> , 2019 , 21, e13113	2.7	8
202	Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis. <i>Advances in Therapy</i> , 2019 , 36, 1771-1777	4.1	20
201	Treatment of Infections Due to MDR Gram-Negative Bacteria. <i>Frontiers in Medicine</i> , 2019 , 6, 74	4.9	116
200	Risk scores and surgery for infective endocarditis: in search of a good predictive score. <i>Scandinavian Cardiovascular Journal</i> , 2019 , 53, 117-124	2	3
199	Early post-liver transplant surgical morbidity in HIV-infected recipients: risk factor for overall survival? A nationwide retrospective study. <i>Transplant International</i> , 2019 , 32, 1044-1052	3	1
198	Diagnostic and therapeutic approach to infectious diseases in solid organ transplant recipients. <i>Intensive Care Medicine</i> , 2019 , 45, 573-591	14.5	25
197	ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. <i>Intensive Care Medicine</i> , 2019 , 45, 789-805	14.5	70
196	Management of reduced vaccine coverage due to 6 years of failure to vaccinate: The Codroipo case, Italy. <i>Vaccine</i> , 2019 , 37, 2294-2297	4.1	1
195	Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. <i>Clinical Infectious Diseases</i> , 2019 , 68, S233-S240	11.6	10
194	KPC-producing <i>Klebsiella pneumoniae</i> gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study. <i>Journal of Global Antimicrobial Resistance</i> , 2019 , 17, 109-111	3.4	3
193	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1912-1918	11.6	9
192	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-producing <i>K. pneumoniae</i> . <i>Clinical Infectious Diseases</i> , 2019 , 68, 355-364	11.6	163
191	Daptomycin-containing regimens for treatment of Gram-positive endocarditis. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 423-434	14.3	5
190	Influence of age on the clinical efficacy of tigecycline in severely ill patients. <i>Journal of Global Antimicrobial Resistance</i> , 2019 , 18, 199-206	3.4	1
189	Screening for carriage of carbapenem-resistant Enterobacteriaceae in settings of high endemicity: a position paper from an Italian working group on CRE infections. <i>Antimicrobial Resistance and Infection Control</i> , 2019 , 8, 136	6.2	10

188	Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2019 , 14, 31-40	4.9	11
187	ECMM CandiReg-A ready to use platform for outbreaks and epidemiological studies. <i>Mycoses</i> , 2019 , 62, 920-927	5.2	10
186	Surgical Complications Requiring an Early Relaparotomy in HIV-Infected Liver Transplant Recipients: Risk Factors and Impact on Survival. <i>Transplantation Proceedings</i> , 2019 , 51, 2977-2980	1.1	2
185	Important new therapies for methicillin-resistant. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 2317-2334	4	12
184	A look at clinical trial design for new antimicrobials for the adult population. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 1037-1046	3.8	4
183	Management of vertebral osteomyelitis over an eight-year period: The UDIPROVE (UDIne PROtocol on VERtebral osteomyelitis). <i>International Journal of Infectious Diseases</i> , 2019 , 89, 116-121	10.5	11
182	Emerging drugs for treating methicillin-resistant. <i>Expert Opinion on Emerging Drugs</i> , 2019 , 24, 191-204	3.7	5
181	Diagnosis and Treatment of Candidemia in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019 , 40, 524-539	3.9	7
180	Challenges and research priorities to progress the impact of antimicrobial stewardship. <i>Drugs in Context</i> , 2019 , 8, 212600	5.2	11
179	The role of fosfomycin for multidrug-resistant gram-negative infections. <i>Current Opinion in Infectious Diseases</i> , 2019 , 32, 617-625	5.4	17
178	Prosthetic joint infections: clinical management, diagnosis, and treatment. <i>Current Opinion in Infectious Diseases</i> , 2019 , 32, 102-112	5.4	4
177	The role of new β -lactamase inhibitors in gram-negative infections. <i>Current Opinion in Infectious Diseases</i> , 2019 , 32, 638-646	5.4	19
176	Current role of oxazolidinones and lipoglycopeptides in skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2019 , 32, 123-129	5.4	5
175	Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study. <i>Infection and Drug Resistance</i> , 2019 , 12, 3607-3623	4.2	22
174	Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI). <i>Antimicrobial Resistance and Infection Control</i> , 2019 , 8, 204	6.2	6
173	Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 99-105	5.5	13
172	Ceftolozane/tazobactam for the treatment of serious <i>Pseudomonas aeruginosa</i> infections: a multicentre nationwide clinical experience. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 408-415	4.3	80
171	Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 266-269	3.8	7

170	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. <i>Mycoses</i> , 2019 , 62, 310-319	5.2	36
169	Rationalizing antimicrobial therapy in the ICU: a narrative review. <i>Intensive Care Medicine</i> , 2019 , 45, 172-189	5.5	79
168	Italian nationwide survey on <i>Pseudomonas aeruginosa</i> from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 664-671	5.1	46
167	Ceftolozane/tazobactam: place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 307-320	5.5	65
166	Predictors of Mortality with <i>Staphylococcus aureus</i> Bacteremia in Elderly Adults. <i>Journal of the American Geriatrics Society</i> , 2018 , 66, 1284-1289	5.6	9
165	Update on new research in Gram-negative infections European Congress of Clinical Microbiology and Infectious Diseases 2017 (22-25 April, Vienna, Austria). <i>Future Science OA</i> , 2018 , 4, FSO270	2.7	
164	Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	34
163	The current role of glycopeptides in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. <i>Journal of Chemotherapy</i> , 2018 , 30, 157-171	2.3	
162	New antibiotics for ventilator-associated pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2018 , 31, 177-186	5.4	43
161	Update on skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2018 , 31, 103	5.4	
160	Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review. <i>Infectious Diseases and Therapy</i> , 2018 , 7, 17-27	6.2	29
159	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. <i>Intensive Care Medicine</i> , 2018 , 44, 189-196	14.5	65
158	When to switch to an oral treatment and/or to discharge a patient with skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2018 , 31, 163-169	5.4	14
157	Independent risk factors for mortality in critically ill patients with candidemia on Italian Internal Medicine Wards. <i>Internal and Emergency Medicine</i> , 2018 , 13, 199-204	3.7	16
156	Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018 , 37, 785-794	5.3	15
155	The role of dalbavancin in skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2018 , 31, 141-147	5.4	17
154	An introduction to the future of echinocandin therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, i2-i3	5.1	
153	What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, i14-i25	5.1	59

152	Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole. <i>IDCases</i> , 2018 , 12, 7-9	2	6
151	Ceftolozane/tazobactam for the treatment of MDR <i>Pseudomonas aeruginosa</i> left ventricular assist device infection as a bridge to heart transplant. <i>Infection</i> , 2018 , 46, 263-265	5.8	16
150	Epidemiological and clinical features of imported malaria at the three main hospitals of the Friuli-Venezia Giulia Region, Italy. <i>Infection, Disease and Health</i> , 2018 , 23, 17-22	4.6	4
149	The role of biofilm forming on mortality in patients with candidemia: a study derived from real world data. <i>Infectious Diseases</i> , 2018 , 50, 214-219	3.1	17
148	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infection. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 244-248	14.3	42
147	A prognostic score for the resolution of bacteremia by Gram-negative bacteria resistant to carbapenems. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018 , 37, 2083-2089	5.3	2
146	Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non- <i>albicans</i> spp. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 1449-1459	2.8	4
145	NGS barcode sequencing in taxonomy and diagnostics, an application in "" pathogenic yeasts with a metagenomic perspective. <i>IMA Fungus</i> , 2018 , 9, 91-105	6.8	13
144	Raising concerns about the Sepsis-3 definitions. <i>World Journal of Emergency Surgery</i> , 2018 , 13, 6	9.2	59
143	Is meropenem MIC increase against KPC-producing <i>Klebsiella pneumoniae</i> correlated with increased resistance rates against other antimicrobials with Gram-negative activity?. <i>Journal of Global Antimicrobial Resistance</i> , 2018 , 14, 238-241	3.4	4
142	Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin. <i>Infection and Drug Resistance</i> , 2018 , 11, 479-488	4.2	10
141	Antimicrobial resistance and treatment: an unmet clinical safety need. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 669-680	4.1	19
140	Isavuconazole shortens the QTc interval. <i>Mycoses</i> , 2018 , 61, 256-260	5.2	36
139	Estimated burden of fungal infections in Italy. <i>Journal of Infection</i> , 2018 , 76, 103-106	18.9	9
138	New Antibiotics for Pneumonia. <i>Clinics in Chest Medicine</i> , 2018 , 39, 853-869	5.3	15
137	2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. <i>World Journal of Emergency Surgery</i> , 2018 , 13, 58	9.2	92
136	Comparison between procalcitonin and C-reactive protein to predict blood culture results in ICU patients. <i>Critical Care</i> , 2018 , 22, 252	10.8	9
135	Role of pharmacists in antimicrobial stewardship programmes. <i>International Journal of Clinical Pharmacy</i> , 2018 , 40, 948-952	2.3	28

134	Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. <i>Infectious Diseases and Therapy</i> , 2018 , 7, 439-455	6.2	214
133	The ideal patient profile for new beta-lactam/beta-lactamase inhibitors. <i>Current Opinion in Infectious Diseases</i> , 2018 , 31, 587-593	5.4	18
132	Rational approach in the management of Pseudomonas aeruginosa infections. <i>Current Opinion in Infectious Diseases</i> , 2018 , 31, 578-586	5.4	24
131	How to manage infections. <i>Drugs in Context</i> , 2018 , 7, 212527	5.2	291
130	Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant/extensively drug-resistant/pandrug-resistant bacteria. <i>Current Opinion in Critical Care</i> , 2018 , 24, 385-393	3.5	56
129	Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 749-761	5.5	58
128	Management of patients with septic shock due to Candida infection. <i>Hospital Practice (1995)</i> , 2018 , 46, 258-265	2.2	4
127	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 984-994	27.4	339
126	Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 1671-1672	2.8	3
125	Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report. <i>Drugs and Therapy Perspectives</i> , 2018 , 34, 402-403	1.5	1
124	Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. <i>Future Microbiology</i> , 2018 , 13, 1081-1094	2.9	11
123	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. <i>Intensive Care Medicine</i> , 2017 , 43, 1187-1197	14.5	66
122	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. <i>Intensive Care Medicine</i> , 2017 , 43, 1225-1238	14.5	90
121	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. <i>Intensive Care Medicine</i> , 2017 , 43, 509-518	14.5	37
120	Pulmonary nodules in African migrants caused by chronic schistosomiasis. <i>Lancet Infectious Diseases</i> , 2017 , 17, e159-e165	25.5	15
119	"Salvage treatment" for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. <i>Intensive Care Medicine</i> , 2017 , 43, 1164-1166	14.5	6
118	Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam. <i>Journal of Global Antimicrobial Resistance</i> , 2017 , 9, 100-102	3.4	14
117	The role of methicillin-resistant Staphylococcus aureus in skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2017 , 30, 150-157	5.4	23

116	How Should We Treat HAP/VAP Caused by Carbapenemase-Producing Enterobacteriaceae?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 301-310	3.9	8
115	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. <i>Transplantation Direct</i> , 2017 , 3, e156	2.3	27
114	¹⁸ F-Fluorodeoxyglucose positron emission tomography and infectious diseases: current applications and future perspectives. <i>Current Opinion in Infectious Diseases</i> , 2017 , 30, 192-200	5.4	10
113	Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. <i>Mycoses</i> , 2017 , 60, 663-667	5.2	11
112	Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1386-1395	5.1	61
111	Higher fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) uptake in tuberculous compared to bacterial spondylodiscitis. <i>Skeletal Radiology</i> , 2017 , 46, 777-783	2.7	15
110	Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. <i>Journal of Chemotherapy</i> , 2017 , 29, 197-214	2.3	54
109	Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 255-258	14.3	50
108	Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 1193-1200	5.5	16
107	Elderly versus non-elderly patients with intra-abdominal candidiasis in the ICU. <i>Minerva Anestesiologica</i> , 2017 , 83, 1126-1136	1.9	8
106	Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review. <i>Journal of NeuroVirology</i> , 2017 , 23, 908-912	3.9	5
105	Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis. <i>Expert Review of Anti-Infective Therapy</i> , 2017 , 15, 807-818	5.5	14
104	Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. <i>Intensive Care Medicine</i> , 2017 , 43, 1464-1475	14.5	117
103	Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	25
102	An Evaluation of the Effectiveness of Risk Minimization Measures for Tigecycline in the European Union. <i>Pharmaceutical Medicine</i> , 2017 , 31, 89-99	2.3	4
101	Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysis. <i>Anesthesiology</i> , 2017 , 126, 890-908	4.3	64
100	Individualizing duration of antibiotic therapy in community-acquired pneumonia. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017 , 45, 191-201	3.5	6
99	Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 333-339	4.7	23

98	Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. <i>Expert Review of Anti-Infective Therapy</i> , 2017 , 15, 55-65	5.5	51
97	Invasive mould infections in the ICU setting: complexities and solutions. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, i39-i47	5.1	67
96	Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality. <i>PLoS ONE</i> , 2017 , 12, e0170236	3.7	38
95	Critically ill migrants with infection: diagnostic considerations for intensive care physicians in Europe. <i>Intensive Care Medicine</i> , 2016 , 42, 245-8	14.5	14
94	Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). <i>World Journal of Emergency Surgery</i> , 2016 , 11, 33	9.2	95
93	Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study. <i>Infection</i> , 2016 , 44, 747-755	5.8	31
92	Exploring ecological modelling to investigate factors governing the colonization success in nosocomial environment of Candida albicans and other pathogenic yeasts. <i>Scientific Reports</i> , 2016 , 6, 26860	4.9	17
91	The current treatment landscape: candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, ii13-ii22	5.1	48
90	Is first-line antimicrobial therapy still adequate to treat MRSA in the ICU? A report from a highly endemic country. <i>Critical Care</i> , 2016 , 20, 246	10.8	7
89	Safety profiles of old and new antimicrobials for the treatment of MRSA infections. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 467-81	4.1	24
88	Bloodstream infections in the Intensive Care Unit. <i>Virulence</i> , 2016 , 7, 267-79	4.7	48
87	Intratracheal Administration of Antimicrobial Agents in Mechanically Ventilated Adults: An International Survey on Delivery Practices and Safety. <i>Respiratory Care</i> , 2016 , 61, 1008-14	2.1	28
86	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 196-207	5.1	104
85	Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?. <i>Critical Care</i> , 2016 , 20, 19	10.8	33
84	Multidrug-resistant Gram-negative bacteria-resistant infections: epidemiology, clinical issues and therapeutic options. <i>Italian Journal of Medicine</i> , 2016 , 10, 364	0.5	13
83	New therapeutic options for respiratory tract infections. <i>Current Opinion in Infectious Diseases</i> , 2016 , 29, 178-86	5.4	6
82	New therapeutic options for skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2016 , 29, 99-108	5.4	15
81	The management of multidrug-resistant Enterobacteriaceae. <i>Current Opinion in Infectious Diseases</i> , 2016 , 29, 583-594	5.4	84

80	Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. <i>Critical Care</i> , 2016 , 20, 125	10.8	57
79	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016 , 20, 133	10.8	70
78	Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. <i>Annals of Intensive Care</i> , 2016 , 6, 35	8.9	47
77	Hot topics in the diagnosis and management of skin and soft-tissue infections. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 19-26	14.3	31
76	Determination of PCT on admission is a useful tool for the assessment of disease severity in travelers with imported Plasmodium falciparum malaria. <i>Acta Parasitologica</i> , 2016 , 61, 412-8	1.7	14
75	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. <i>European Journal of Internal Medicine</i> , 2016 , 34, 45-53	3.9	6
74	Candidemia in Patients with Body Temperature Below 37°C and Admitted to Internal Medicine Wards: Assessment of Risk Factors. <i>American Journal of Medicine</i> , 2016 , 129, 1330.e1-1330.e6	2.4	15
73	Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients. <i>Intensive Care Medicine</i> , 2015 , 41, 366-8	14.5	12
72	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. <i>Critical Care</i> , 2015 , 19, 33	10.8	83
71	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. <i>Intensive Care Medicine</i> , 2015 , 41, 1601-10	14.5	125
70	Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). <i>Clinical Infectious Diseases</i> , 2015 , 61, 324-31	11.6	96
69	Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45 Suppl 1, S1-14	14.3	17
68	Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2133-43	5.1	334
67	Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. <i>Haematologica</i> , 2015 , 100, e373-6	6.6	38
66	Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections: a critical agenda. <i>Future Microbiology</i> , 2015 , 10, 283-94	2.9	29
65	Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. <i>Intensive Care Medicine</i> , 2015 , 41, 776-95	14.5	105
64	Task force on management and prevention of Acinetobacter baumannii infections in the ICU. <i>Intensive Care Medicine</i> , 2015 , 41, 2057-75	14.5	95
63	Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience. <i>Intensive Care Medicine</i> , 2015 , 41, 2026-8	14.5	6

62	Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials. <i>International Journal of Antimicrobial Agents</i> , 2015 , 46, 346-50	14.3	16
61	Overview of Fungal Infections--The Italian Experience. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015 , 36, 796-805	3.9	10
60	Linezolid underexposure in a patient co-treated with venlafaxine. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1285-6	2.8	7
59	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study--authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2922	5.1	45
58	Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on <i>Staphylococcus aureus</i> . <i>Clinical Infectious Diseases</i> , 2015 , 60, 787-96	11.6	20
57	"Excess Mortality" and Colistin-Tigecycline for Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Bacteremia. <i>Critical Care Medicine</i> , 2015 , 43, e470-1	1.4	4
56	New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. <i>Current Opinion in Critical Care</i> , 2015 , 21, 402-11	3.5	55
55	Clinical and therapeutic aspects of candidemia: a five year single centre study. <i>PLoS ONE</i> , 2015 , 10, e0123534	3.5	76
54	Development of novel antibacterial drugs to combat multiple resistant organisms. <i>Langenbeck's Archives of Surgery</i> , 2015 , 400, 153-65	3.4	40
53	Delafloxacin for the treatment of respiratory and skin infections. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 433-42	5.9	25
52	Diabetic Foot Team 2015 , 4923-4955		
51	Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2585-51	5.1	15
50	DALI: defining antibiotic levels in intensive care unit patients: are current β -lactam antibiotic doses sufficient for critically ill patients?. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1072-83	11.6	564
49	Infective endocarditis in elderly: an Italian prospective multi-center observational study. <i>International Journal of Cardiology</i> , 2014 , 177, 636-8	3.2	10
48	Predictive models for identification of hospitalized patients harboring KPC-producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3514-20	5.9	62
47	How to manage aspergillosis in non-neutropenic intensive care unit patients. <i>Critical Care</i> , 2014 , 18, 458	10.8	28
46	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. <i>Critical Care</i> , 2014 , 18, R99	10.8	65
45	A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. <i>Intensive Care Medicine</i> , 2014 , 40, 839-45	14.5	173

44	SDD and colistin resistance: end of a dream?. <i>Intensive Care Medicine</i> , 2014 , 40, 1066-7	14.5	8
43	Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. <i>Future Microbiology</i> , 2014 , 9, 1053-69	2.9	34
42	Antibiotic stewardship challenges in the management of community-acquired infections for prevention of escalating antibiotic resistance. <i>Journal of Global Antimicrobial Resistance</i> , 2014 , 2, 245-253	3.4	27
41	Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 570-1	14.3	7
40	Eravacycline for the treatment of intra-abdominal infections. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 1575-84	5.9	38
39	Current antibiotic management of prosthetic joint infections in Italy: the Udine strategy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69 Suppl 1, i41-5	5.1	14
38	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 395-404	35.1	405
37	Pros and cons of liver transplantation in human immunodeficiency virus infected recipients. <i>World Journal of Gastroenterology</i> , 2014 , 20, 5353-62	5.6	13
36	Diabetic Foot Team 2014 , 1-40		
35	Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant <i>Acinetobacter baumannii</i> : a multicenter, randomized clinical trial. <i>Clinical Infectious Diseases</i> , 2013 , 57, 349-58	11.6	255
34	Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 4167-72	9.7	153
33	New antibiotics for bad bugs: where are we?. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2013 , 12, 22	6.2	276
32	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. <i>Intensive Care Medicine</i> , 2013 , 39, 2092-106	14.5	138
31	Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68 Suppl 2, ii37-44	5.1	17
30	Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68 Suppl 2, ii25-35	5.1	32
29	Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68 Suppl 2, ii5-14	5.1	15
28	Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68 Suppl 2, ii45-55	5.1	13
27	Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68 Suppl 2, ii15-24	5.1	23

26	The Management of the Infected Diabetic Foot. <i>Current Diabetes Reviews</i> , 2013 , 9, 7-24	2.7	13
25	A survey on infection management practices in Italian ICUs. <i>Critical Care</i> , 2012 , 16, R221	10.8	7
24	Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2012 , 10, 585-96	5.5	54
23	Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. <i>Clinical Infectious Diseases</i> , 2012 , 55, 943-50	11.6	705
22	New treatment options against gram-negative organisms. <i>Critical Care</i> , 2011 , 15, 215	10.8	75
21	Will new antimicrobials overcome resistance among Gram-negatives?. <i>Expert Review of Anti-Infective Therapy</i> , 2011 , 9, 909-22	5.5	33
20	Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3485-90	5.9	117
19	Development of antibiotics for Gram-negatives: where now?. <i>Clinical Investigation</i> , 2011 , 1, 211-227		3
18	Clinical performance of the (1,3)- β -glucan assay in early diagnosis of nosocomial Candida bloodstream infections. <i>Vaccine Journal</i> , 2011 , 18, 2113-7		47
17	Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. <i>PLoS ONE</i> , 2011 , 6, e24198	3.7	144
16	High-dose daptomycin in documented Staphylococcus aureus infections. <i>International Journal of Antimicrobial Agents</i> , 2010 , 36, 459-61	14.3	61
15	Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. <i>Critical Care</i> , 2010 , 14, 244	10.8	40
14	Tigecycline use in serious nosocomial infections: a drug use evaluation. <i>BMC Infectious Diseases</i> , 2010 , 10, 287	4	35
13	Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 625-9	5.1	71
12	The role of telavancin in the treatment of MRSA infections in hospital. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 521-9	5.9	10
11	Long course of daptomycin in the treatment of meticillin-resistant Staphylococcus epidermidis endocarditis and spondylodiscitis. <i>International Journal of Antimicrobial Agents</i> , 2009 , 34, 290-1	14.3	5
10	Why is community-associated MRSA spreading across the world and how will it change clinical practice?. <i>International Journal of Antimicrobial Agents</i> , 2009 , 34 Suppl 1, S15-9	14.3	75
9	Current status of newer carbapenems. <i>Current Medicinal Chemistry</i> , 2009 , 16, 564-75	4.3	41

8	Novel beta-lactam antibiotics and inhibitor combinations. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 285-96	5.9	33
7	Drug treatment for multidrug-resistant <i>Acinetobacter baumannii</i> infections. <i>Future Microbiology</i> , 2008 , 3, 649-60	2.9	57
6	<i>Pseudomonas aeruginosa</i> serious infections: mono or combination antimicrobial therapy?. <i>Current Medicinal Chemistry</i> , 2008 , 15, 517-22	4.3	26
5	Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 433-5	5.1	39
4	Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 58, 325-31	2.9	89
3	<i>Candida</i> infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2006 , 4, 875-85	5.5	17
2	Epidemiological trends in nosocomial candidemia in intensive care. <i>BMC Infectious Diseases</i> , 2006 , 6, 21	4	230
1	Successful treatment of methicillin-resistant <i>Staphylococcus aureus</i> endocarditis with linezolid. <i>International Journal of Antimicrobial Agents</i> , 2004 , 24, 83-4	14.3	21